Integra LifeSciences Holdings Corporation - Common Stock (IART)
12.21
+0.34 (2.86%)
NASDAQ · Last Trade: Jun 27th, 1:28 AM EDT
NEW YORK CITY, NY / ACCESS Newswire / June 20, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Via ACCESS Newswire · June 20, 2025
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · June 18, 2025
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · June 15, 2025
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · June 10, 2025
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · June 6, 2025

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · June 2, 2025

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · May 28, 2025
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · May 22, 2025
NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · May 18, 2025
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or “the Company”) (NASDAQ: IART) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · May 15, 2025
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · May 13, 2025
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · May 9, 2025
PHILADELPHIA, May 06, 2025 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · May 6, 2025
PHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ: AKRO):
By Grabar Law Office · Via GlobeNewswire · May 5, 2025
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · April 28, 2025
PHILADELPHIA, April 25, 2025 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · April 25, 2025
PHILADELPHIA, April 24, 2025 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · April 24, 2025
PHILADELPHIA, April 22, 2025 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · April 22, 2025
PHILADELPHIA , April 11, 2025 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · April 11, 2025
PHILADELPHIA, April 07, 2025 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · April 7, 2025
PHILADELPHIA, April 04, 2025 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · April 4, 2025
PHILADELPHIA, March 31, 2025 (GLOBE NEWSWIRE) -- Holley Inc. (NYSE: HLLY) f/ka Empower Ltd. (NYSE: EMPW):
By Grabar Law Office · Via GlobeNewswire · March 31, 2025
PHILADELPHIA, March 27, 2025 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · March 27, 2025
PHILADELPHIA, March 25, 2025 (GLOBE NEWSWIRE) --
By Grabar Law Office · Via GlobeNewswire · March 25, 2025
PHILADELPHIA, March 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ: AKRO):
By Grabar Law Office · Via GlobeNewswire · March 24, 2025